Posters
« Back
Validation of Factor IIa Assay for Dalteparin Sodium
EP28863
Poster Title: Validation of Factor IIa Assay for Dalteparin Sodium
Submitted on 23 Jul 2018
Author(s): Dr Amitabha De, Kiran Shah, Prajakta Ambre, Jyoti Gupta
Affiliations: KRISHGEN BIOSYSTEMS
Poster Views: 664
View poster »


Poster Information
Abstract: Dalteparin anti-FIIa is a chromogenic assay intended for the quantitative determination of Dalteparin in purified solutions by measurement of factor IIa inhibition activity. The kit can be used as per microtiter plate protocol.

The inhibitory effect of anti-thrombin III (AT-III) on thrombin, factor IIa and other coagulation serine proteases in plasma is increased several thousand-fold by Dalteparin. This inhibition accounts for the anticoagulant effect of Dalteparin.

The quantitative determination of Dalteparin levels by the measurement of their anti-IIa activity is a necessary tool for monitoring treatment efficacy.

The kit and its components were used to run samples of biological solutions and plasma to validate and estimate dalteparin sodium.

It was concluded that the kits were accurate and sensitive for the estimation of dalteparin sodium and dalteparin injection as per USP guidelines.
Summary: Validation of a Chromogenic Assay using Factor IIa for estimation of Dalteprain Sodium and Dalteparin Injection. References: Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. C. Gadiko, S. K. Tippabhotla, S. Thota, M. Nakkawar, R. Cheerla, M.R. Betha, and V. Vobalaboina. Journal Drug Assess v.2(1); 2013 PMC4937650.
Pharmacodynamics of Intravenous and Subcutaneous Tinzaparin and Heparin in Healthy Volunteers. Am J Health Syst Pharm. 2001;58(17)
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Technological advancement: ensuring reliable data in protein arrays
Maja Kowalewska, Sam Hawkings, Marisa Chong-Kwan and Joan Salvatella

Rare Presentation of a Rare Tumour: Case Report of Sclerosing Stromal Tumour with Meig’s Syndrome and Raised Serum Cancer Antigen 125.
Kushal Joshi, Tauseef Ashraf

Genetic Engineering in Male Sterility for Hybrid Variety Development
Abir Hasan Joy

VITVO: Mimicking In Vivo Complexity By The Innovative 3D Model
Olivia Candini1, Giulia Grisendi1, Elisabetta Manuela Foppiani1, Matteo Brogli1, Beatrice Aramini2, Valentina Masciale3, Carlotta Spano1, Tiziana Petrachi4, Elena Veronesi4, Pierfranco Conte5,6, Giorgio Mari1 & Massimo Dominici1,3

Digiceuticals
Helana Lutfi and Shaban Nuredini